Learn More About Trodelvy Patient Support Services

2021 Year in Review - Triple-Negative Breast Cancer —January 20, 2022

Categories:

Breast Cancer

Trodelvy (sacituzumab govitecan-hziy) copayment assistance, reimbursement support, and patient assistance programs are available for eligible patients.1 Prior authorizations and appeals must be submitted by the physician’s office.2 Patients with any type of government insurance are not eligible for the Trodelvy Savings Program.2 To be eligible for this program, patients must meet certain criteria. The patient pays no out-of-pocket costs for Trodelvy once enrolled, with a maximum benefit of $25,000 per year.2

The Gilead Patient Assistance Program provides free access to Trodelvy for patients who are uninsured or underinsured.2 Patients must meet specific eligibility requirements to qualify for assistance.2

Patients with Medicare or other government insurance who require copay or coinsurance assistance for Trodelvy may be eligible for assistance from an independent copay assistance foundation.2 Patients can work with case managers to determine their high-level eligibility for Trodelvy coverage through an independent copay assistance foundation.2 Case managers and nurse navigators can provide information on any available foundations if copay assistance is needed. A foundation will determine the patient’s eligibility for copay or coinsurance assistance based on their individual criteria and will contact the patient directly on the application process, fully independent of Gilead and its agents. Gilead and its representatives make no assurances about compensation for any service or material.2

The Trodelvy Savings Program is for commercially or privately insured patients, offering up to $25,000 in savings on out-of-pocket payments for Trodelvy 180-mg single-dose vials. Only the cost of Trodelvy is covered by the program; the patient is responsible for the cost of treatments and office visits.2

Any claims funded, paid, or reimbursed in whole or in part by Medicaid, Medicare, or other federal or state healthcare programs are not supported by this program.2

Trodelvy Access Support case managers can provide information about independent third-party groups that may be able to help with the cost of treatment to patients who are unable to afford their medication (including those with Medicare, Medicaid, or other government-sponsored insurance). Trodelvy coverage, coding, and billing requirements vary by plan and patient.2

Further information can be found at https://trodelvyhcp.com/hcp/mTNBC/access-support or www.needymeds.org/brand-drug/name/Trodelvy.

References

  1. Needymeds.com. Trodelvy. Updated September 2021. www.needymeds.org/brand-drug/name/Trodelvy. Accessed November 15, 2021.
  2. Trodelvyhcp.com. Trodelvy access support. Updated September 2021. https://trodelvyhcp.com/hcp/mTNBC/access-support. Accessed November 15, 2021.
Related Articles
What AYAs with Breast Cancer and Their Providers Tell Us About Survivorship Needs
Heather Becker, PhD, Molly McAdam, MPH, Sharyn Malatok, MPA, Emily Croce, MSN, APRN, CPNP-PC, Eunju Choi, PhD, Elaine Gonzales, CN-BA, CHW, CHWI
|
April 2022 Vol 13, No 4
Sacituzumab Govitecan-hziy in the Treatment of HR-Positive Breast Cancer
2021 Year in Review - Triple-Negative Breast Cancer
Patients with endocrine-resistant HR-positive/HER2-negative metastatic breast cancer require novel therapeutic alternatives as a result of the poor outcomes of currently available later-line medications.
An Unmet Need in HR-Positive Endocrine-Resistant Breast Cancer
2021 Year in Review - Triple-Negative Breast Cancer
The emergence of innovative targeted therapy in combination with endocrine therapy has shown improvement in HR-positive breast cancer results, but the US Food and Drug Administration–approved combinations all include endocrine therapies in their regimens, leaving an unmet need in patients who develop endocrine resistance.
Last modified: January 20, 2022

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code